Dr. Shanu Modi

Dr. Shanu Modi, MD, is a widely respected breast medical oncologist specializing in the treatment of breast cancer, with a focus on metastatic disease and emerging targeted therapies. She is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), where she plays a central role in the Breast Medicine Service and serves as an investigator in the Early Drug Development Program. Dr. Modi earned her medical degree from Rutgers New Jersey Medical School, completed her residency in internal medicine at NYU Langone Medical Center, and pursued fellowship training in medical oncology at MSKCC. She is board-certified in Internal Medicine and Medical Oncology.

Dr. Modi is internationally recognized for her clinical and research leadership in HER2-positive and HER2-low breast cancer. She has led pioneering studies that helped define a new subtype of breast cancer and contributed to the approval of innovative antibody-drug conjugates, including trastuzumab deruxtecan. Her translational work integrates biomarker discovery with clinical trial development, with the goal of refining personalized treatment strategies for advanced breast cancer. Her research has been published in top-tier oncology journals, and she is an invited speaker at major national and international conferences.

In addition to her clinical and scientific contributions, Dr. Modi is a dedicated mentor and educator to fellows and junior faculty at MSKCC. She collaborates with multidisciplinary teams to design and implement novel clinical trials and plays an active role in national oncology working groups. Through her commitment to clinical innovation, translational research, and leadership in breast cancer therapeutics, Dr. Modi continues to shape the future of breast cancer care on both institutional and global levels.